Bridging all oral <scp>DAA</scp> therapy from wait time to post‐liver transplant to improve <scp>HCV</scp> eradication?

Abstract

Waiting for direct antiviral agents combinations, our findings not only support the use of sofosbuvir plus ribavirin as the first-line treatment in all patients on the LT waiting list, but also suggest to bridge treatment to the post-transplant period in case HCV RNA undetectability for at least 30 days has not been achieved at the time of LT.